CX-908 / CytomX - LARVOL DELTA

CX-908, a PROBODY® T cell engager targeting CDH3 and CD3, induces tumor regressions and improves the therapeutic window in preclinical studies (SITC 2025) - "Additionally, studies performed in non-human primates demonstrate that CX-908 is well tolerated with 100-fold improved tolerability compared to the unmasked form and shows significantly reduced cytokine release.Conclusions CX-908 shows strong anti-tumor efficacy and an improved tolerability profile compared to the unmasked TCE in preclinical studies. These data indicate that CX-908 has a wide predicted therapeutic window and support the potential to target CDH3 positive solid tumors clinically.Ethics Approval Rodent studies were approved by the CytomX Therapeutics Institutional Animal Care and Use Committee and non human primate studies were approved by the Institutional Animal Care and Use Committee of Alta Sciences or Inovtiv."

Preclinical • Breast Cancer • Lung Cancer • Oncology • Solid Tumor • CDH3